Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant differences in the local conformations and kinetic properties of heart and lung ACEs demonstrate tissue specificity of ACE and provide a structural base for the development of mAbs able to distinguish heart and lung ACEs as a potential blood test for predicting atrial fibrillation risk.
|
28771512 |
2017 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population.
|
18496132 |
2008 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Age, smoking history, diabetes mellitus,hypertension frequency, angiotensin converting enzyme inhibitor-angiotensin receptor blocker use, CHA₂DS₂VASc and HAS-BLED scores, serum sST2 level, left atrium (LA) end-diastolic diameter, LA volume and LA volume index were related to AF recurrence.
|
30238709 |
2018 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results suggested an association between ACE insertion/deletion and AF risk.
|
20826259 |
2010 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting.
|
27179719 |
2016 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although activation of the renin-angiotensin-aldosterone system (RAAS) now appears to play a role in the pathophysiology of atrial fibrillation (AF), it remains to be determined if ACE genotype impacts response to conventional AAD therapy in patients with AF.
|
17556195 |
2007 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the role of the ACE I/D polymorphism in relation to the different clinical forms of AF, lone and secondary nonvalvular atrial fibrillation (NVAF).
|
17113662 |
2007 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the association of RAS gene polymorphisms with nonfamilial structural AF and may provide the rationale for clinical trials to investigate the use of ACE inhibitor or angiotensin II antagonist in the treatment of structural AF.
|
15023884 |
2004 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the association of the angiotensin-converting enzyme 2350 G/A polymorphism with atrial fibrillation in Han Chinese patients with essential hypertension.
|
24270955 |
2013 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
An ACE-dependent increase in the amounts of activated Erk1/Erk2 in atrial interstitial cells may contribute as a molecular mechanism for the development of atrial fibrosis in patients with AF.
|
10807475 |
2000 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We identified 21 SNPs and the angiotensin-converting enzyme insertion/deletion polymorphism that were reported to be associated with AF in the literature.
|
21056700 |
2011 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the association between polymorphism in angiotensinogen (AGT) and angiotensin-converting enzyme gene and risk of acquired AF in a pair-matched case-control study conducted in Chinese Hans.
|
19932491 |
2010 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation.
|
21436211 |
2011 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effects of angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on thrombogenicity in AF remain incompletely elucidated.
|
28980280 |
2018 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In patients with CHF, the presence of AF was significantly associated with certain ACE and eNOS genotypes.
|
16818212 |
2006 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a study in a Japanese population, it was reported that the angiotensin-converting enzyme insertion/deletion polymorphism was not associated with atrial fibrillation.
|
14631130 |
2003 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study suggests that the presence of the D allele in hypertensive patients with AF is associated with attenuation of type-I collagen degradation, and that therapy with ACE inhibitors increases degradation of collagen type I.
|
17927479 |
2007 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Classic RAS blockers such as angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent AF by affecting the accumulation of the EAT, representing a useful therapeutic strategy for preventing AF especially in patients with heart failure and known left ventricular dysfunction.
|
31375968 |
2020 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
The purpose of this study was to investigate whether response to antiarrhythmic drug (AAD) therapy in patients with AF is modulated by the ACE I/D polymorphism.
|
17556195 |
2007 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and statins were of statistical significance for stroke risks.The majority of AF patients post-RFAs was of high stroke risk and received warfarin thromboprophylaxis in accordance with national guidelines.
|
29381974 |
2017 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation.
|
30067937 |
2018 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
After optimal up-titration of BBs and angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), mean HR in patients with AF was 73 ± 15 beats/minute (bpm), 36% had resting HR ≤65 bpm.
|
28393567 |
2017 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with the ACE D/D genotype appear to be at higher risk of AF.
|
26041129 |
2015 |
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis suggests that there is insufficient evidence to demonstrate an association between ACE I/D polymorphism and AF risk.
|
21076147 |
2011 |
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
This article reviews clinical trials on the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for the prevention of AF.
|
20636314 |
2010 |